| abstract |
The present invention includes at least one siRNA that hybridizes to a coding or non-coding mRNA, wherein the hybridization induces degradation of the mRNA or is involved in its translation, expression or a pathological condition encoded by the mRNA. Provided are compositions used for the prevention and / or treatment of pathological conditions that inhibit protein expression and formulated for continuous systemic administration, and devices comprising such modes of administration. [Selection figure] None |